The Bifurcation of Consciousness: A Comprehensive Analysis of Psychedelic Microdosing, Neurocognitive Dynamics, and Global Regulatory Frameworks (2025)

The Bifurcation of Consciousness: A Comprehensive Analysis of Psychedelic Microdosing, Neurocognitive Dynamics, and Global Regulatory Frameworks (2025) Executive Summary The practice of psychedelic microdosing—the regimented consumption of sub-hallucinogenic quantities of serotonergic compounds—has evolved from a niche bio-hacking curiosity into a subject of intense pharmacological, psychological, and regulatory scrutiny. As of late 2025, the scientific narrative surrounding microdosing has fractured into two distinct realities: the subjective, often anecdotal reports of enhanced wellbeing and creativity, and the objective, clinical data indicating complex trade-offs in cognitive control and emotional stability. This white paper provides an exhaustive analysis of the state of microdosing research, anchored by the foundational observational work of Polito and Stevenson (2019) and the transformative 2025 meta-analysis by Pinhas et al. It explores the paradoxical findings where microdosing appears to alleviate symptoms of depression while simultaneously degrading specific executive functions and potentially increasing neuroticism. Crucially, this updated report also examines the "New Infrastructure" of research and commerce emerging in late 2025. It details how Decentralized Science (DeSci) and IP-NFTs are bypassing traditional pharmaceutical funding bottlenecks to finance microdosing trials, and how AI-driven Real-World Evidence (RWE) is validating the observational data that traditional Randomized Controlled Trials (RCTs) often miss.33 By synthesizing over five years of empirical data, this report posits that microdosing is not a panacea for cognitive enhancement but a pharmacological modulator that "loosens" top-down cognitive rigidity—a mechanism that facilitates absorption and openness at the cost of inhibitory control. 1. Introduction: The Microdosing Phenomenon in Historical and Cultural Context The renaissance of psychedelic science in the 21st century has been characterized by a dual focus: the high-dose, therapeutic breakthrough model pioneered by institutions like Johns Hopkins and Imperial College London, and the low-dose, chronic administration model known as microdosing. While the former seeks to induce a profound, often mystical state of "ego dissolution" to treat intractable psychiatric conditions, the latter aims to integrate the pharmacological benefits of psychedelics into daily life without functional impairment. 1.1 Defining the Protocol Microdosing typically involves the ingestion of approximately one-tenth to one-twentieth of a "recreational" dose of a classic serotonergic psychedelic, most commonly psilocybin (0.1g–0.5g of dried biomass) or lysergic acid diethylamide (LSD, 6–20 µg).1 The defining feature of a microdose is that it is sub-perceptual or sub-sensorium; the user should not experience overt visual hallucinations, distortion of reality, or significant intoxication. Instead, the practice targets "delicate changes" in neurochemistry intended to boost focus, enhance creativity, and improve emotional baseline functioning.3 Two primary protocols have dominated the cultural landscape: The Fadiman Protocol: Developed by Dr. James Fadiman, involving dosing once every three days (Day 1: Dose, Day 2: Afterglow, Day 3: Baseline) to prevent physiological tolerance downregulation of 5-HT2A receptors. The Stamets Stack: Proposed by mycologist Paul Stamets, combining psilocybin with niacin (Vitamin B3) and Lion's Mane mushroom (Hericium erinaceus) to theoretically synergize neurogenesis and peripheral circulation. 1.2 The Media Narrative vs. Clinical Reality Throughout the late 2010s, media narratives positioned microdosing as a "productivity hack" utilized by Silicon Valley professionals to achieve flow states and competitive advantage. Claims of enhanced problem-solving, reduced social anxiety, and improved "convergent thinking" proliferated. However, as the scientific community mobilized to verify these claims, a discrepancy emerged between the robust subjective reports of users and the often equivocal or contradictory objective data collected in controlled settings.3 The tension between these two datasets—the subjective experience of the user and the objective measurements of the clinician—forms the core inquiry of this report. The following sections dissect the pivotal studies that have defined this field, revealing a complex pharmacological reality that challenges the simplistic "wellness" narrative. 2. The Polito and Stevenson Study: Establishing the Baseline In 2019, Vince Polito and Richard J. Stevenson published a landmark study in PLOS One titled "A systematic study of microdosing psychedelics." This investigation represented one of the first rigorous attempts to systematically track the experiences of microdosers using a longitudinal design, moving beyond retrospective surveys to capture daily fluctuations in psychological functioning.2 2.1 Methodological Innovations: The Precursor to RWE Conducting research on Schedule I substances presents profound legal and ethical barriers. To circumvent laws prohibiting the administration of illicit drugs to healthy volunteers, Polito and Stevenson utilized a naturalistic, observational design. They recruited participants who were already intending to microdose, thereby tracking preexisting behavior rather than initiating it.3 In 2025 terms, this methodology is recognized as an early form of Real-World Evidence (RWE) generation. Unlike the "bedrock" Randomized Controlled Trials (RCTs) which are often inefficient and fail to represent real-world diversity, this observational data leverages the "virtual population" of active users.33 This approach allowed for the collection of high-fidelity data on "real-world" usage patterns, paving the way for the AI-driven causal inference models now used to validate such datasets.33 2.2 The Positive Cluster: Absorption and Mood The results of the Polito study provided empirical validation for several positive anecdotal claims. Participants reported a general increase in psychological functioning on dosing days, distinct from baseline days. Reduction in Depression and Stress: Analyses of pre- and post-study measures revealed statistically significant reductions in depression and stress scores.3 Polito noted that no participant in the study exhibited clinical challenges with depression or stress during the dosing regimen, suggesting a protective or prophylactic effect against negative affect.3 Focus and Absorption: A critical finding was the reduction in "mind wandering" and a concurrent increase in "absorption"—the capacity to become deeply immersed in sensory or imaginative experiences.3 This aligns with the "flow state" often described by users, where the distinction between the self and the task blurs, facilitating deep work or creative engagement. Creativity Estimates: Participants reported feeling more creative and imaginative on dosing days.3 However, it is crucial to distinguish between feeling creative and performing creatively on standardized tests—a distinction that later studies, such as the Pinhas meta-analysis, would rigorously interrogate. 2.3 The Neuroticism Paradox: The Hidden Signal Perhaps the most significant—and widely overlooked—finding of the Polito study was the impact of microdosing on personality structure. Personality traits, particularly those in the Five-Factor Model (Openness, Conscientiousness, Extraversion, Agreeableness, Neuroticism), are typically regarded as stable in adulthood. However, Polito and Stevenson observed a statistically significant increase in neuroticism following the six-week microdosing period.3 Neuroticism is characterized by a tendency toward emotional instability, anxiety, moodiness, and increased sensitivity to negative stressors. This finding contradicts the popular narrative of microdosing as a purely stabilizing practice. While depression scores (a state) decreased, neuroticism (a trait) increased. This suggests a complex mechanism where microdosing might increase emotional lability or sensitivity. The Sensitivity Hypothesis: The same mechanism that increases "absorption" and "openness" (making the user more receptive to art, nature, or ideas) may also make the user more porous to stress and anxiety.7 Without the "insulation" of normal cognitive rigidity, the microdoser becomes more chemically vulnerable to their environment. Duration Effects: The study found a negative correlation between the duration of prior microdosing experience and neuroticism.8 This implies two possibilities: either long-term users habituate to this sensitivity, or those who experience the initial spike in neuroticism drop out of the practice, leaving a survivorship bias of resilient users. 2.4 The Role of Expectancy To contextualize these pharmacological findings, Polito conducted a secondary study on the beliefs of 263 microdosers. The results revealed a massive expectancy bias: participants universally believed microdosing would deliver large, wide-ranging benefits.6 Crucially, the effects participants expected did not match the effects observed. Users did not expect to become more neurotic, yet they did. This suggests that the increase in neuroticism is a genuine pharmacological signal, distinct from the placebo effect that likely drives some of the mood-related improvements.2 3. The Cognitive Control Crisis: The 2025 Pinhas Meta-Analysis As research progressed into the mid-2020s, the focus shifted from observational studies to rigorous, double-blind, placebo-controlled trials. The definitive work in this era is the 2025 systematic review and meta-analysis by Pinhas et al., published in Neuroscience & Biobehavioral Reviews. This study aggregated data from 14 controlled trials (N=1,614) to evaluate the cognitive effects of microdosing with high statistical power.1 3.1 The Failure of Cognitive Enhancement The Pinhas analysis delivered a sobering verdict on the "smart drug" narrative. The study analyzed 59 effect sizes across multiple cognitive domains and found no detectable beneficial effects on general intelligence, memory, or fluid reasoning.1 The widespread belief that microdosing acts as a limitless-style cognitive enhancer was not supported by the aggregate data of controlled trials. 3.2 The Impairment of Cognitive Control More critically, the meta-analysis identified a significant decrease in cognitive control.1 Cognitive control (or executive control) refers to the top-down mental processes that allow individuals to regulate their behavior, inhibit inappropriate responses, and filter out irrelevant stimuli in service of a goal. Operational Measures: This impairment was observed in tasks such as the Stroop Test (where one must inhibit reading a word to name its color) and the Go/No-Go task (where one must withhold a motor response to a specific stimulus).10 Magnitude and Consistency: The impairment was robust across substance types (LSD vs. Psilocybin), dosages (within the microdose range), and duration of use (1 day vs. 42 days).1 3.3 Practical Implications of Reduced Control The reduction in cognitive control has profound real-world implications. While a deficit in inhibitory control might be subjectively experienced as "thinking outside the box" or reduced rigid thinking (creativity), in a safety-critical context, it represents a liability. Workplace Safety: For professions requiring rapid, high-stakes decision-making or the suppression of impulsive responses (e.g., heavy machinery operation, surgery, air traffic control), a pharmacologically induced reduction in cognitive control is a significant contraindication.12 The "Double-Edged Sword": The Pinhas findings suggest that the very mechanism that makes microdosing therapeutic for depression (breaking rigid patterns of thought) makes it detrimental for tasks requiring rigid focus and inhibition. The brain cannot simultaneously be "loose" enough to rewrite trauma and "tight" enough to perform high-precision executive tasks without trade-offs. 4. The New Infrastructure: AI, DeSci, and the "Liquid" Trial While the clinical data has been mixed, the infrastructure for researching and distributing microdosing therapies has undergone a radical transformation by 2025. The convergence of Artificial Intelligence (AI) and blockchain-based Decentralized Science (DeSci) has created a parallel R&D ecosystem that bypasses traditional pharmaceutical bottlenecks.33 4.1 Decentralized Science (DeSci) and IP-NFTs Traditional clinical trials are prohibitively expensive and slow, creating a "Valley of Death" for novel therapeutics like microdosing protocols that may not have strong patent protection (as psilocybin is a natural compound). To solve this, the industry has pivoted toward IP-NFTs (Intellectual Property Non-Fungible Tokens).33 The Molecule & VitaDAO Model: Platforms like Molecule and VitaDAO have successfully tokenized research data and intellectual property. This allows a global, decentralized organization (DAO) to fund research in exchange for governance rights over the resulting IP.33 University of Toronto Microdosing Study: A prime example of this model is the University of Toronto's large-scale human microdosing study. Funded via the Molecule Catalyst platform, this study produces "preliminary insights and a dataset" which are treated as liquid assets. The data is not just published; it is transacted on-chain, allowing researchers to monetize the raw data of microdosing trials directly to other developers or AI modelers. 4.2 AI-Driven Real-World Evidence (RWE) The industry has recognized that traditional RCTs often fail to capture the "inter-individual differences" in drug response.33 The new standard, endorsed by the FDA's "Advancing Real-World Evidence Program," involves augmenting trials with data from electronic health records and patient registries.33 Causal Inference: Advanced machine learning models (Causal ML) are now used to "clean" observational microdosing data (like that collected by Polito) to establish causality. This allows researchers to distinguish between the placebo effect (noted by Szigeti) and the pharmacological signal (noted by Pinhas) without running thousands of physical trials.33 In Silico "Virtual Populations": Companies are now using AI to create "virtual populations" to model drug toxicity and efficacy in under-represented groups (e.g., postmenopausal women) before physical dosing occurs. This "in silico pharmacology" is rapidly accelerating the safety profiling of chronic microdosing regimens.33 4.3 The "Digital Borders" of Compliance As microdosing products move globally, they face a "compliance gauntlet" of conflicting regulations (e.g., US state-level "track-and-trace" vs. EU-GMP). Reg-Tech Gateways: New software platforms like BackboneIQ serve as "digital customs" brokers. They act as API bridges that translate data between incompatible systems—for example, converting a US "Metrc" compliance report into an "EU-GMP" validation document required for export to Europe. This digital infrastructure is the only way legal microdosing products (like truffles from the Netherlands) can potentially navigate the fragmented global market.33 5. Neurobiology and Mechanisms of Action To understand why microdosing might simultaneously improve "absorption" while degrading "control" and increasing "neuroticism," we must examine the underlying neurobiology of serotonergic psychedelics. 5.1 The 5-HT2A Pathway and Cortical Entropy Psychedelics act primarily as agonists at the serotonin 2A (5-HT2A) receptor. These receptors are densely populated in the high-level cortical regions of the brain, particularly within the Default Mode Network (DMN)—the system responsible for self-referential processing, autobiographical memory, and the stability of the "ego".13 Activation of 5-HT2A receptors leads to a depolarization of deep-layer pyramidal neurons and a desynchronization of oscillatory rhythms (alpha waves).12 This process introduces "entropy" or disorder into the brain's activity. Macrodoses: High entropy leads to a collapse of the DMN and the profound altered states of consciousness used in psychedelic-assisted therapy. Microdoses: Low levels of entropy do not collapse the DMN but destabilize it slightly. This destabilization reduces the brain's ability to maintain rigid top-down control.1 5.2 The REBUS Model: "Relaxed Beliefs Under Psychedelics" The REBUS model, proposed by Carhart-Harris and Friston, posits that psychedelics lower the precision of "priors"—the high-level expectations the brain uses to predict sensory input and regulate emotion.16 Mechanism of Neuroticism: By relaxing these priors, the brain becomes more sensitive to bottom-up sensory and emotional information. If the user is in a negative environment or possesses latent anxiety, the "shield" of their priors is weakened, allowing stress to penetrate more deeply. This manifests psychometrically as an increase in neuroticism.17 Mechanism of Cognitive Control Failure: Inhibitory control relies on strong top-down priors (e.g., "Do not press the button when you see X"). By relaxing these priors, microdosing fundamentally undermines the neural architecture required for inhibition tasks.1 6. Clinical Development and Corporate Pipelines (2025) While grassroots microdosing remains prevalent, the corporate pharmaceutical sector has recognized the limitations of the "wellness" model and pivoted toward targeted clinical indications. As of 2025, specific biopharmaceutical entities are pursuing low-dose indications with rigorous FDA/EMA-compliant trials. 6.1 Diamond Therapeutics: Targeting Anxiety (GAD) Diamond Therapeutics has emerged as a key player in the low-dose space, distinguishing itself from the "macrodose-therapy" model of companies like Compass Pathways. The Phase 2a GAD Trial: In 2025, Diamond Therapeutics initiated a Phase 2a clinical trial evaluating "sub-perceptual" doses of psilocybin for Generalized Anxiety Disorder (GAD).18 This is a randomized, double-blind, placebo-controlled trial utilizing a 3 mg dose (significantly lower than the standard 25 mg macrodose). Take-Home Protocol: Crucially, this is the first Health Canada-approved trial to allow patients to take the investigational drug at home, rather than in a clinic.19 This signals a shift toward treating psilocybin as a chronic medication (like an SSRI) rather than an acute intervention. 6.2 MindMed: LSD and the MM-120 Program MindMed has focused on MM-120 (lysergide D-tartrate), a proprietary LSD formulation. While their primary success has been with single-dose administrations for GAD (where they achieved Breakthrough Therapy Designation), their research into low-dose effects continues to inform the field. Time Perception: MindMed's data suggests that microdosing LSD (10–20 µg) induces temporal dilation (over-reproduction of time intervals) even in the absence of subjective effects.12 This confirms that sub-perceptual doses have measurable neurocognitive impacts, validating the biological activity of the microdose beyond placebo. 7. Global Regulatory Frameworks in 2025 The legal status of psychedelics has fractured globally by 2025, creating a complex patchwork of access models ranging from full medicalization to decriminalization and strict prohibition. 7.1 Australia: The Medical Model Pioneer Australia stands as the global leader in the rescheduling of psychedelics. Effective July 1, 2023, the Therapeutic Goods Administration (TGA) rescheduled psilocybin and MDMA from Schedule 9 (Prohibited Substance) to Schedule 8 (Controlled Drug) for specific indications.21 The "Macrodose-Only" Restriction: Crucially, this rescheduling applies only to the treatment of Treatment-Resistant Depression (psilocybin) and PTSD (MDMA) by authorized psychiatrists. It does not legalize self-administered microdosing. The TGA explicitly restricts prescribing to "Authorised Prescribers" who must oversee the administration, effectively barring the take-home microdosing model due to safety and diversion concerns.23 7.2 Canada: The Special Access Program (SAP) Canada utilizes the Special Access Program (SAP), amended in 2022 to allow practitioners to request access to restricted drugs for patients with serious or life-threatening conditions.25 Access Volumes: Health Canada authorized over 100 requests in 2024, but the program remains a bottleneck designed for "last-resort" therapy.27 Like Australia, the SAP is geared toward psychedelic-assisted psychotherapy (macrodosing), not chronic microdosing, although Diamond Therapeutics' clinical trials operate under specific Health Canada exemptions.19 7.3 The Netherlands: The "Truffle" Loophole The Netherlands remains unique in Europe. While psilocybin mushrooms are illegal, psilocybin sclerotia (magic truffles) are not classified under the Dutch Opium Act.28 Commercial Standardization: This legal distinction has allowed companies like Red Light Holland to legally produce and sell standardized "iMicrodose" packs.28 The Netherlands serves as the primary global hub for legal, consumer-grade microdosing products, providing a natural experiment in widespread access. 7.4 United States: The Federal-State Schism In 2025, the US presents a dichotomy. Federally, psilocybin remains a Schedule I substance with no accepted medical use.30 State-Level Access: Oregon and Colorado have implemented regulated access models (e.g., Colorado's Natural Medicine Health Act) which allow for "healing centers" and decriminalize personal possession.30 However, these state laws do not permit the retail sale of microdoses. FDA Outlook: The FDA has granted Breakthrough Therapy Designation to psilocybin and LSD for anxiety and depression, but approval is strictly for high-dose, supervised clinical models. There is currently no federal movement toward legalizing the sale of microdoses for at-home use.31 8. Safety, Physiology, and the Future Outlook As the popularity of microdosing persists, concerns regarding long-term physiological safety have moved to the forefront of the research agenda. 8.1 The Valvular Heart Disease Risk A primary safety concern regarding chronic microdosing is the potential for valvular heart disease (VHD). The 5-HT2B receptor, which is stimulated by both psilocybin and LSD, is implicated in the proliferation of cardiac valvular interstitial cells. Chronic activation of 5-HT2B (as seen with the withdrawn diet drug Fen-Phen) can lead to cardiac fibrosis.32 Status in 2025: While acute macrodoses are considered cardiac-safe, the daily or near-daily activation of 5-HT2B receptors via microdosing poses a theoretical risk that has yet to be ruled out by long-term epidemiological data. 8.2 The Bifurcation of Use The future of microdosing appears to be splitting into two distinct paths: The Clinical Path: Exemplified by Diamond Therapeutics and supported by AI-driven DeSci trials, this path treats microdosing as a low-dose pharmaceutical intervention for specific anxiety disorders, subject to rigorous trials and prescription controls. The Wellness/Recreational Path: This path continues in the grey market and decriminalized zones, driven by user reports of creativity and flow, despite the lack of objective cognitive enhancement data. 8.3 Conclusion The findings from the groundbreaking studies of Polito, Pinhas, and Szigeti suggest that the popular conception of microdosing as a "free lunch"—a way to gain cognitive enhancement without intoxication—is scientifically flawed. The practice appears to trade cognitive control for sensory absorption, and emotional stability for emotional sensitivity. However, the rapid maturation of the "New Infrastructure"—including DeSci funding models, IP-NFTs, and AI-driven Real-World Evidence—promises to accelerate our understanding of these trade-offs. As we move through 2025, the scientific community is better equipped than ever to disentangle the placebo from the pharmacological, and the subjective "feeling" of brilliance from the objective reality of cognitive performance. Table 1: Summary of Key Findings on Microdosing (2019-2025) Domain Finding Source Study Implications Depression/Stress Significant reduction in symptoms on dosing days. Polito & Stevenson (2019) Potential prophylactic utility for mood disorders. Neuroticism Significant increase after 6 weeks of use. Polito & Stevenson (2019) Indicates increased emotional lability/sensitivity; contraindication for unstable personality types. Cognitive Control Significant impairment (Stroop/Go-No-Go tasks). Pinhas et al. (2025) Safety risks for driving/machinery; undermines "productivity hack" narrative. General Cognition No significant improvement in memory or intelligence. Pinhas et al. (2025) Benefits likely subjective or placebo-driven. Subjective Mood Improvement matched by active placebo. Szigeti et al. (2021) High expectancy bias drives positive subjective reports. Table 2: 2025 Global Regulatory Status of Psilocybin Jurisdiction Legal Classification Access Model Microdosing Status Australia Schedule 8 (Controlled) Prescription by Authorised Psychiatrist (TRD only). Illegal without Rx. No take-home access. Canada Schedule III (CDSA) Special Access Program (SAP) for serious illness. Illegal. Specific clinical trials (Diamond Therapeutics) allowed. Netherlands Legal (Truffles) Retail sales (Smart Shops). Legal. Global hub for commercial microdosing. USA (Federal) Schedule I FDA Clinical Trials only. Illegal. USA (State) Varies (CO/OR Decrim) Regulated Healing Centers. Decriminalized possession; no retail sales. Works cited Effects of Psychedelic Microdosing on Cognitive Functions: A Systematic Review and Meta-Analysis - PubMed, accessed December 15, 2025, https://pubmed.ncbi.nlm.nih.gov/41314362/ (PDF) A systematic study of microdosing psychedelics - ResearchGate, accessed December 15, 2025, https://www.researchgate.net/publication/330921297_A_systematic_study_of_microdosing_psychedelics A systematic study of microdosing psychedelics - PubMed, accessed December 15, 2025, https://pubmed.ncbi.nlm.nih.gov/30726251/ A systematic study of microdosing psychedelics - PMC - NIH, accessed December 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6364961/ Microdosing Psychedelics - Vince Polito, accessed December 15, 2025, https://www.vincep.cogscience.org/project/microdosing/ A systematic study of microdosing psychedelics | PLOS One - Research journals, accessed December 15, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0211023 Exploring the relationship between microdosing, personality and emotional insight: A prospective study in - AKJournals, accessed December 15, 2025, https://akjournals.com/view/journals/2054/5/1/article-p9.xml Exploring the relationship between microdosing, personality and emotional insight: A prospective study - AKJournals, accessed December 15, 2025, https://akjournals.com/downloadpdf/view/journals/2054/5/1/article-p9.pdf Exploring the relationship between microdosing, personality and emotional insight: A prospective study - Macquarie University, accessed December 15, 2025, https://research-management.mq.edu.au/ws/portalfiles/portal/166028378/158394408.pdf Impact of psilocybin on cognitive function: A systematic review - PMC - NIH, accessed December 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11612538/ Microdosing psychedelics has no impact on cognitive function in naturalistic settings, accessed December 15, 2025, https://www.researchgate.net/publication/373019485_Microdosing_psychedelics_has_no_impact_on_cognitive_function_in_naturalistic_settings Effects of Psychedelic Microdosing on Cognitive Functions: A Systematic Review and Meta-Analysis | Request PDF - ResearchGate, accessed December 15, 2025, https://www.researchgate.net/publication/398028911_Effects_of_Psychedelic_Microdosing_on_Cognitive_Functions_A_Systematic_Review_and_Meta-Analysis (PDF) Default Mode Network Modulation by Psychedelics: A Systematic Review, accessed December 15, 2025, https://www.researchgate.net/publication/364651800_Default_Mode_Network_Modulation_by_Psychedelics_A_Systematic_Review Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics - PMC, accessed December 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11078317/ Psychedelic compounds directly excite 5-HT2A Layer 5 Pyramidal Neurons in the Prefrontal Cortex through a 5-HT2A Gq -mediated activation mechanism | bioRxiv, accessed December 15, 2025, https://www.biorxiv.org/content/10.1101/2022.11.15.516655v1.full-text Default Mode Network Modulation by Psychedelics: A Systematic Review - PMC, accessed December 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10032309/ Catalyst for change: Psilocybin's antidepressant mechanisms—A systematic review - PMC, accessed December 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12099018/ Study Details | NCT06969170 | Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder, accessed December 15, 2025, https://clinicaltrials.gov/study/NCT06969170 Diamond Therapeutics initiates dosing in first-ever Phase 2a clinical trial evaluating low-dose psilocybin for anxiety - FirstWord Pharma, accessed December 15, 2025, https://firstwordpharma.com/story/5985159 Diamond Therapeutics Announces Health Canada Approval of Phase 2 Clinical Trial with Low-Dose Psilocybin - Psychedelic Alpha, accessed December 15, 2025, https://psychedelicalpha.com/news/diamond-therapeutics-announces-health-canada-approval-of-phase-2-clinical-trial-with-low-dose-psilocybin Psilocybine and MDMA - NSW Health, accessed December 15, 2025, https://www.health.nsw.gov.au/pharmaceutical/Pages/psilocybine-and-mdma.aspx Re-scheduling of psilocybin and MDMA in the Poisons Standard: questions and answers, accessed December 15, 2025, https://www.tga.gov.au/resources/publication/scheduling-decisions-final/notice-final-decision-amend-or-not-amend-current-poisons-standard-june-2022-acms-38-psilocybine-and-mdma/re-scheduling-psilocybin-and-mdma-poisons-standard-questions-and-answers Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists | Therapeutic Goods Administration (TGA), accessed December 15, 2025, https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists Update on MDMA and psilocybin access and safeguards from 1 July 2023, accessed December 15, 2025, https://www.tga.gov.au/news/news-articles/update-mdma-and-psilocybin-access-and-safeguards-1-july-2023 Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy - Canada.ca, accessed December 15, 2025, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html Expanded access to psychedelic treatments: comparing American and Canadian policies - PMC - NIH, accessed December 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11840896/ Federal court rules Health Canada decision to block experiential psilocybin training was unreasonable | CBC News, accessed December 15, 2025, https://www.cbc.ca/news/canada/health-canada-psilocybin-1.7566289 Inside Red Light Holland's Plan to Bring Psilocybin Products to the Global Market, accessed December 15, 2025, https://cannabisindustryjournal.com/feature_article/taking-psilocybin-global-with-red-light-holland/ Are truffles really legal? Your questions explained, accessed December 15, 2025, https://whennaturecalls.nl/blogs/when-nature-calls-blogs/are-truffles-really-legal Is psilocybin microdosing legal in the USA in 2025? - Grow Barato, accessed December 15, 2025, https://www.growbarato.net/blog/en/legality-of-microdosing-of-psilocybin-in-2025/ Psychedelic Therapy in 2025 -New Research Reveals Surprising Clinical Outcomes, accessed December 15, 2025, https://globalrph.com/2025/10/psychedelic-therapy-in-2025-new-research-reveals-surprising-clinical-outcomes/ Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research - NIH, accessed December 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11311906/ The New Infrastructure_ Synthesizing AI, DeSci, and dMRV for the Next Generation of Regulated Bio-Economies.pdf